To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
New Silk Route to invest in Indian drug company
Nectar Lifesciences has received board approval to issue up to 26m equity shares to the private equity firm.
